神经外科医师大会循证指南:功能性垂体腺瘤围手术期内科管理
本指南由神经外科医师大会基于系统综述制定,检索Embase和PubMed至2021年6月,最终纳入44项研究。主要推荐包括:经蝶术后无尿崩症患者限制液体(每日1000-1500 mL,约7天)以降低迟发性低钠血症和再入院风险;ACTH分泌肿瘤术后72小时内查晨皮质醇以预测肾上腺功能不全和缓解;不推荐生长激素分泌肿瘤术前使用生长抑素类似物改善手术或内科结局。
要点
- 经蝶术后无尿崩症患者建议限制液体每日1000-1500 mL约7天,降低迟发性低钠血症和再入院风险。
- ACTH分泌肿瘤患者术后72小时内查晨皮质醇(±ACTH)以预测肾上腺功能不全和疾病缓解。
- 不推荐生长激素分泌肿瘤患者术前使用生长抑素类似物来改善手术或内科结局。
核心结论
- 推荐所有经蝶术后无尿崩症患者限制液体,并常规术后查晨皮质醇用于库欣病,但不推荐肢端肥大症患者术前使用生长抑素类似物。
研究设计与样本
- 系统综述由神经外科医师大会制定,检索Embase和PubMed从1946年至2021年6月,纳入44项研究,证据以III级为主。
主要发现
- 共鉴定1953篇摘要,124篇全文审查,44篇纳入分析。
- 文献支持限制液体(每日1000-1500 mL,约术后7天)伴或不伴常规血钠检查可降低迟发性低钠血症和再入院风险。
- 文献支持ACTH分泌肿瘤术后72小时内查晨皮质醇(±ACTH)预测肾上腺功能不全和疾病缓解。
- 围手术期使用生长抑素类似物治疗生长激素分泌肿瘤不推荐用于改善手术或内科结局。
关键数值与推荐
- 限制液体:每日1000-1500 mL,约术后7天,适用于经蝶术后无尿崩症患者。
- 晨皮质醇检测:术后72小时内,适用于ACTH分泌肿瘤患者,可±ACTH。
- 不推荐生长抑素类似物用于生长激素分泌肿瘤的围手术期治疗。
临床怎么用
- 经蝶术后无尿崩症患者可考虑限制液体每日1000-1500 mL约7天以降低迟发性低钠血症和再入院风险。
- ACTH分泌肿瘤患者术后72小时内检测晨皮质醇以评估肾上腺功能不全和疾病缓解。
- 生长激素分泌肿瘤患者不应为改善手术或内科结局而术前使用生长抑素类似物。
局限性
- 证据以III级为主,整体证据级别有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Standardized perioperative management of patients with functioning pituitary adenomas is important for optimal medical and surgical outcomes. Review of the literature to evaluate the impacts of (1) postoperative fluid restriction and sodium level checks to prevent delayed hyponatremia and hospital-related readmissions, (2) preoperative somatostatin analog (SSA) medical treatment in patients with growth hormone-secreting tumors and its effects on surgical and medical outcomes, and (3) immediate postoperative pituitary hormone testing in patients with adrenocorticotropic hormone (ACTH)-secreting tumors to predict adrenal insufficiency and disease remission. METHODS: Systematic literature search using Embase and PubMed from 1946 to June 2021. RESULTS: A total of 1953 abstracts were identified for review: 124 studies were selected for full-text review, and 44 studies were included in the analyses. Overall, based on predominantly level III evidence, the literature supported the following: (1) fluid restriction (1000-1500 mL/day for ∼7 postoperative days), with/without a routine serum sodium check, to lower the risk of delayed hyponatremia and hospital-related readmission, and (2) basal morning serum cortisol (±ACTH levels), within the immediate postoperative period (≤72 h) for patients with ACTH-secreting tumors to predict adrenal insufficiency and disease remission. Conversely, perioperative treatment of patients with growth hormone-secreting tumors with a SSA is not recommended to improve surgical or medical outcomes. CONCLUSION: Limited fluid restriction is recommended for all patients after trans-sphenoidal surgery (without diabetes insipidus), as is routine postoperative morning cortisol testing in patients with Cushing disease, but not somatostatin presurgical treatment in acromegalic patients.
引用
- Turin CG, Kerr JM, Post KD, et al. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines for the Role of Medical Perioperative Management for Patients With Functioning Pituitary Adenomas. Neurosurgery. 2025. PMID: 40815128. doi:10.1227/neu.0000000000003608
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。